MedTech

NATROX® O₂, a continuous topical oxygen therapy, is gaining attention for its potential role in managing late radiation tissue injury following Mohs surgery. 

A case series published in the WOUNDS journal explored the efficacy of cTOT in supporting wound healing, particularly in advanced-age patients post-Mohs surgery.

Such chronic radiation wounds and late radiation tissue injuries present challenges in wound management. NATROX® O₂, ranked No.1 on our MedTech 50 innovation ranking last year, delivers oxygen directly to the wound site, aiming to promote collagen synthesis and mitigate the effects of radiation therapy.

Windy Cole, a co-author of the study, highlights NATROX® O₂’s potential impact on fragile skin and impaired wound healing, noting observations of accelerated healing and pain alleviation. Emma Woodmansey, another co-author, emphasises the importance of exploring innovative wound care solutions.

Inotec – NATROX® O₂ device heals wounds with humidified oxygen

The case series reports outcomes associated with NATROX® O₂, including reductions in wound size, enhancements in tissue granulation, and reductions in pain levels. These findings suggest potential improvements in treatment strategies for late radiation tissue injury patients.

The publication of NATROX® O₂-related research in WOUNDS journal signifies a step forward in understanding potential applications of this therapy in wound management.

In the pursuit of evidence-based wound care, continued research into NATROX® O₂ and other innovative therapies may contribute to improved treatment approaches and patient outcomes in the field of post-surgical wound care.

Topical oxygen therapy upgraded to ‘Level 1’ in DFU treatment guidelines